SCHEMBL14429033

SCHEMBL14429033

Nc1ncnc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H](N)[C@@H](O)[C@H]1O

nearest known ligand 0.87

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA3 P0DMS8 4/20 0.87
POLB P06746 1/20 0.87
ADORA1 P30542 2/20 0.86
DPP4 P27487 1/20 0.86
MEN1 O00255 1/20 0.86
SLC28A1 O00337 1/20 0.86
MAP3K7 O43318 1/20 0.86
SLC28A2 O43868 1/20 0.86
GAPDH P04406 1/20 0.86
MAPK1 P28482 1/20 0.86
ADORA2A P29274 1/20 0.86
ADORA2B P29275 1/20 0.86
STAT6 P42226 1/20 0.86
PI4KA P42356 1/20 0.86
KMT2A Q03164 1/20 0.86
SMN1; SMN2 Q16637 1/20 0.86
PI4K2B Q8TCG2 1/20 0.86
DOT1L Q8TEK3 1/20 0.86
SLC29A1 Q99808 1/20 0.86
PI4K2A Q9BTU6 1/20 0.86

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28669338 0.93 ADORA3 (1.00) ADORA3POLBADORA1DPP4MEN1
SCHEMBL29537510 0.93 ADORA3 (1.00) ADORA3POLBADORA1DPP4MEN1
SCHEMBL14580082 0.93 ADORA3 (1.00) ADORA3POLBADORA1DPP4MEN1
SCHEMBL598129 0.93 ADORA3 (1.00) ADORA3POLBADORA1DPP4MEN1
SCHEMBL598131 0.93 ADORA3 (1.00) ADORA3POLBADORA1DPP4MEN1
SCHEMBL14565261 0.93 ADORA3 (1.00) ADORA3POLBADORA1DPP4MEN1
SCHEMBL598130 0.93 ADORA3 (1.00) ADORA3POLBADORA1DPP4MEN1
SCHEMBL939272 0.93 ADORA3 (1.00) ADORA3POLBADORA1DPP4MEN1
SCHEMBL7153060 0.93 ADORA3 (1.00) ADORA3POLBADORA1DPP4MEN1
SCHEMBL4204378 0.93 ADORA3 (1.00) ADORA3POLBADORA1DPP4MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070185063-A1 Seven-membered ring nucleosides IDENIX PHARMACEUTICALS, INC. 2007-08-09 US disclosed
US-20070185063-A1 Seven-membered ring nucleosides IDENIX PHARMACEUTICALS, INC. 2007-08-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070185063-A1 Seven-membered ring nucleosides NSUN2, NSUN3, HAVCR2 ADORA3 332/4885POLB 368/4885ADORA1 678/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.